• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by AtriCure Inc.

    11/14/24 8:00:04 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care
    Get the next $ATRC alert in real time by email
    SC 13G 1 o102246sc13g.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.    )*

     

    AtriCure, Inc.
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)

     

      04963C209  
      (CUSIP Number)  
     
    September 30, 2024
    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      x Rule 13d-1(b)
         
      ¨ Rule 13d-1(c)
         
      ¨ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

       
     

     

    CUSIP No.  04963C209
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Hood River Capital Management LLC 46-1294859

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)x

    (b)¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

         

    6

    SHARED VOTING POWER

     

         

    7

    SOLE DISPOSITIVE POWER

     

    2,830,600

    8

    SHARED DISPOSITIVE POWER

     

         

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,830,600

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.81%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    IA

     

       
     

     

    Item 1(a). Name of Issuer:
       
      AtriCure, Inc.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      7555 Innovation Way  Mason, OH  45040
       
    Item 2(a). Name of Person Filing:
       
      Hood River Capital Management LLC
       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
       
      2373 PGA Blvd., Suite 200   Palm Beach Gardens, FL  33410
       
    Item 2(c). Citizenship:
       
      USA
       
    Item 2(d). Title of Class of Securities:
       
      COMMON
       
    Item 2(e). CUSIP Number:  04963C209

     

       
     

     

    Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
      (j) ¨ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:      

     

    Item 4. Ownership.
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount Beneficially Owned: 2,830,600   
      (b) Percent of Class: 5.81%
      (c) Number of shares as to which such person has:
        (i) sole power to vote or to direct the vote: 0   
        (ii) shared power to vote or to direct the vote: 0   
        (iii) sole power to dispose or to direct the disposition of: 2,830,600   
        (iv) shared power to dispose or to direct the disposition of: 0   

     

       
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.
       
     Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
      Not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
      Not applicable.
       
    Item 9. Notice of Dissolution of Group.
       
      Not applicable.
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect for the time being.

     

       
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      October 2, 2024  
      Date  
         
      /s/ Robert Schmaltz  
      Signature  
         
      Robert Schmaltz, CCO & COO  
      Name/Title  

     

     

     

     

     

     

    Get the next $ATRC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATRC

    DatePrice TargetRatingAnalyst
    12/17/2024$40.00Overweight
    Analyst
    4/23/2024$32.00Perform → Outperform
    Oppenheimer
    10/23/2023$60.00Mkt Outperform
    JMP Securities
    9/29/2023$56.00Buy
    UBS
    2/16/2022$120.00 → $88.00Buy
    Canaccord Genuity
    2/16/2022$92.00 → $79.00Buy
    Needham
    11/4/2021$90.00 → $92.00Buy
    Needham
    11/4/2021$100.00 → $110.00Outperform
    SVB Leerink
    More analyst ratings

    $ATRC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst resumed coverage on AtriCure with a new price target

    Analyst resumed coverage of AtriCure with a rating of Overweight and set a new price target of $40.00

    12/17/24 7:29:01 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded AtriCure from Perform to Outperform and set a new price target of $32.00

    4/23/24 6:23:54 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    JMP Securities initiated coverage on AtriCure with a new price target

    JMP Securities initiated coverage of AtriCure with a rating of Mkt Outperform and set a new price target of $60.00

    10/23/23 7:18:47 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AtriCure Announces the First Patients Treated with Novel Dual Energy Platform

    New technology combines Pulsed Field Ablation (PFA) and Advanced Radiofrequency Ablation with AtriCure's EnCompass® clamp to reduce treatment time for surgical ablation patients AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced successful first-in-human treatments using its novel dual energy platform that integrates Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA). The procedures were performed by Dr. Adrian Pick in collaboration with the site Principal Investigator Professor Jayme Bennetts, at Victorian He

    12/11/25 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference

    AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 37th Annual Healthcare Conference. AtriCure's management is scheduled to participate in a fireside discussion on Tuesday, December 2, 2025, at 10:00 a.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related c

    11/18/25 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025

    Worldwide revenue of $134.3 million – an increase of 15.8% year over year (15.1% constant currency) Net loss of $0.3 million – an improvement of $7.6 million year over year Adjusted EBITDA of $17.8 million – an increase of $9.9 million year over year Generated $30.1 million of cash in the third quarter and $25.1 million year to date AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2025 financial results. "Our third quarter results demonstrate strong execution and patient focus across the business. We are

    10/29/25 4:01:00 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    SEC Filings

    View All

    SEC Form 144 filed by AtriCure Inc.

    144 - AtriCure, Inc. (0001323885) (Subject)

    11/25/25 4:06:42 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by AtriCure Inc.

    144 - AtriCure, Inc. (0001323885) (Subject)

    11/24/25 5:41:59 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by AtriCure Inc.

    10-Q - AtriCure, Inc. (0001323885) (Filer)

    10/30/25 12:21:59 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CEO, & Director Carrel Michael H gifted 4,000 shares, decreasing direct ownership by 0.58% to 687,377 units (SEC Form 4)

    4 - AtriCure, Inc. (0001323885) (Issuer)

    12/12/25 8:26:40 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    Director Wehrwein Sven exercised 10,000 shares at a strike of $19.95 and sold $376,578 worth of shares (10,000 units at $37.66) (SEC Form 4)

    4 - AtriCure, Inc. (0001323885) (Issuer)

    11/26/25 4:43:11 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    Chief Mktg & Strategy Officer Noznesky Justin J sold $192,640 worth of shares (5,166 units at $37.29), decreasing direct ownership by 6% to 78,798 units (SEC Form 4)

    4 - AtriCure, Inc. (0001323885) (Issuer)

    11/26/25 4:41:44 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Privitera Salvatore bought $111,250 worth of shares (5,000 units at $22.25), increasing direct ownership by 5% to 103,290 units (SEC Form 4)

    4 - AtriCure, Inc. (0001323885) (Issuer)

    5/31/24 4:12:34 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Leadership Updates

    Live Leadership Updates

    View All

    AtriCure Appoints Shlomi Nachman to the Board of Directors

    AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors. Mr. Nachman's long and distinguished career in the medical device industry has placed him at the forefront of new market development and growth, serving most recently as Company Group Chairman within Johnson & Johnson's Medical Devices business. Mr. Nachman has over 25 years of experience in the medical device industry and is currently on the board of several private medical device companies, as well as the Arnold and Mable Beck

    1/4/24 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer

    AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effective today. Ms. Yount will have responsibility for global Human Resources activities. "We are excited to have Deborah joining us at AtriCure," said Michael Carrel, President and Chief Executive Officer. "She brings an incredible amount of industry and human capital expertise as we enter a period of accelerated growth. Our opportunities to address the global Afib epidemic and help patients manage post-operative pain are profo

    6/1/22 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Financials

    Live finance-specific insights

    View All

    AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025

    Worldwide revenue of $134.3 million – an increase of 15.8% year over year (15.1% constant currency) Net loss of $0.3 million – an improvement of $7.6 million year over year Adjusted EBITDA of $17.8 million – an increase of $9.9 million year over year Generated $30.1 million of cash in the third quarter and $25.1 million year to date AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2025 financial results. "Our third quarter results demonstrate strong execution and patient focus across the business. We are

    10/29/25 4:01:00 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure to Announce Third Quarter 2025 Financial Results

    AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2025 financial results on Wednesday, October 29, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, October 29, 2025, to discuss its third quarter 2025 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at

    10/8/25 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025

    Worldwide revenue of $136.1 million – an increase of 17.1% year over year (16.5% constant currency) Net loss of $6.2 million – an improvement of $1.8 million year over year Adjusted EBITDA of $15.4 million – an increase of $7.6 million year over year Generated $17.9 million of cash in the quarter Completed enrollment of all 6,500 patients in the ground-breaking LeAAPS trial AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2025 financial results. "Our stellar results reflect the power of innovation and the

    7/29/25 4:01:00 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by AtriCure Inc.

    SC 13G - AtriCure, Inc. (0001323885) (Subject)

    11/14/24 8:00:04 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by AtriCure Inc. (Amendment)

    SC 13G/A - AtriCure, Inc. (0001323885) (Subject)

    2/14/24 2:56:38 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by AtriCure Inc. (Amendment)

    SC 13G/A - AtriCure, Inc. (0001323885) (Subject)

    2/13/24 4:58:56 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care